An Ultra-sensitive LC Method for the Simultaneous Determination of Paracetamol, Carbamazepine, Losartan and Ciprofloxacin in Bulk Drug, Pharmaceutical Formulation and Human Serum by Programming the Detector

Najma Sultana, Muhammad Saeed Arayne, Saeeda Nadir Ali

Department of Chemistry, University of Karachi, Karachi, Pakistan.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Karachi, Karachi, Pakistan.

DOI: 10.4236/ajac.2013.41004                

Abstract

An ultra-sensitive LC method for the simultaneous quantitation of paracetamol, carbamazepine, losartan and ciprofloxacin have been developed and validated following the ICH guidelines at isobestic point and by programming the detector at individual wavelength of each component. The components were eluted by 50:50 v/v acetonitrile-water (pH 3.0) using a Bondapak, C₁₈ (10 μm, 25 × 0.46 cm) column at flow rate of 1.0 mL·min^-1 with detection wavelength 240 nm at isobestic point and 245, 230, 206 and 272 nm for paracetamol, carbamazepine, losartan potassium and ciprofloxacin respectively by programming the detector. Linearity was found to be 0.5 - 24, 0.25 - 8.0, 0.4 - 12 and 0.75 - 10 μg·mL^-1 (R² > 0.999) with detection limits 99, 20, 30 and 6.0 ng·mL^-1 respectively. Comparison study with time program method showed more sensitivity with calibration range of 0.4 - 12, 0.2 - 6.0, 0.1 - 3.0 and 0.25 - 8.0 μg·mL^-1 (R² > 0.999) and LOD values 29, 11, 2.0 and 5.0 ng·mL^-1 respectively. Percent recoveries >98.37% from pharmaceutical formulation and human serum samples and RSD < 2% for inter-day and intra-day assay were obtained. The method was found to be robust and can be successfully applied for the determination of studied drugs in, pharmaceutical formulations and human serum without interference of excipients or endogenous components of serum.

Keywords

Paracetamol; Carbamazepine; Losartan; Ciprofloxacin; Time Program

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	N. Sultana, M. S. Arayne and W. Shahzad, “Simultaneous Determination of Ceftriaxone Sodium and Statin Drugs in Pharmaceutical Formulations and Human Serum by RP-HPLC,” Journal of the Chilean Chemical Society, Vol. 55, No. 2, 2010, pp. 193-198. doi:10.4067/S0717-97072010000200010
[2]	N. Sultana, M. S. Arayne, R. Siddiqui and S. Naveed, “RP-HPLC Method for the Simultaneous Determination of Lisinopril and NSAIDs in API, Pharmaceutical Formulations and Human Serum,” American Journal of Analytical Chemistry, Vol. 3, No. 2, 2012, pp. 147-152. doi:10.4236/ajac.2012.32021
[3]	M. S. Arayne, N. Sultana, A. Tabassum, S. N. Ali and S. Naveed, “Simultaneous LC Deter-mination of Rosuvastatin, Lisinopril, Captopril, and Enalapril in API, Pharmaceuti- cal Dosage Formulations, and Human Se-rum,” Medicinal Chemistry Research, Vol. 21, No. 12, 2012, pp. 4542- 4548. doi:10.1007/s00044-012-9997-x
[4]	N. Sultana, M. S. Arayne, S. Shamim and A. Naz, “Validated Method for the Simultaneous Determination of Gemifloxacin and H2-receptor Antagonists in Bulk, Phar- maceutical Formulations and Human Serum by RP-HPLC; In-vitro Applications,” Journal of the Chinese Chemical Society, Vol. 58, No. 5, 2011, pp. 629-636. doi:10.1002/jccs.201190098
[5]	N. Sultana, M. Saeed Arayne, S. N. Ali and M. H. Zuberi, “Simultaneous Determination of Glipizide and Glimepride by Rp-Hplc in Dosage Formulations and in Human Serum,” Medicinal Chemistry Research, Vol. 21, No. 9, 2012, pp. 2443-2448. doi:10.1007/s00044-011-9772-4
[6]	M. S. Arayne, N. Sultana, S. B. S. Rizvi and U. Haroon, “In Vitro Drug Interaction Studies of Atorvastatin with Ciprofloxacin, Gatifloxacin, and Ofloxacin,” Medicinal Chemistry Research, Vol. 19, No. 8, 2010, pp. 717-731. doi:10.1007/s00044-009-9225-5
[7]	K. Bergman, L. Muller and S. W. Teigen, “The Genotox- icity and Carcinogenicity of Paracetamol: A Regulatory (Re) View,” Mutation Research/Fundamental and Mo- lecular Mechanisms of Mutagenesis, Vol. 349, No. 2, 1996, pp. 263-288.
[8]	R. B. Lipton, M. E. Bigal, K. B. Kolodner, P. B. Gorelick, K. Wilks, M. Schoebelock and G. Davidai, “Acetamino-phen in the Treatment of Headaches Associated with Dipyridamole-Aspirin Combination,” Neurology, Vol. 63, No. 6, 2004, pp. 1099-1101. doi:10.1212/01.WNL.0000138494.66691.07
[9]	C. J. Nikles, M. Yelland, C. Del Mar and D. Wilkinson, “The Role of Paracetamol in Chronic Pain: An Evidence-Based Approach,” American Journal of Therapeutics, Vol. 12, No. 1, 2005, pp. 80-91. doi:10.1097/00045391-200501000-00011
[10]	J. B. Leikin and F. P. Paloucek, “Poisoning and Toxicology, Handbook,” 4th Edition, Informa Healthcare, New York, 2008.
[11]	L. J. Dodds, Ed., “Drugs in Use: Clinical Case Studies for Pharmacists,” Pharmaceutical Press, London, 2010, p. 357.
[12]	D. J. Carini, D. D. Christ, J. V. Duncia and M. E. Pierce, “The Discovery and Development of Angiotensin II Antagonists,” In: R. T. Borchardt, R. M. Freidinger, T. K. Sawyer and P. L. Smith, Eds., Integration of Pharmaceutical Discovery and Development: Case Histories, Plenum Press, New York, 1998, pp. 29-56.
[13]	A. A. J. Torriero, E. Salinas, J. Raba and J. J. Silber, “Sensitive Determination of Ciprofloxacin and Norfloxacin in Biological Fluids Using an Enzymatic Rotating Biosensor,” Biosensors and Bioelectronics, Vol. 22, No. 1, 2006, pp. 109-115. doi:10.1016/j.bios.2005.12.004
[14]	V. P. Godse, M. N. Deodhar, A. V. Bhosale, R. A. Sonawane, P. S. Sakpal, D. D. Borkar and Y. S. Bafana, “Reverse Phase HPLC Method for Determination of Aceclofenac and Paracetamol in Tablet Dosage Form,” Asian Journal of Research Chemistry, Vol. 2, No. 1, 2009, pp. 37-40.
[15]	D. T. T. An and V. D. Hoang, “Simultaneous Determination of Paracetamol and Codeine Phosphate in Combined Tablets by First-Order Derivative and Ratio Spectra First-Order Derivative UV Spectrophotometry,” Asian Journal of Research Chemistry, Vol. 2, No. 2, 2009, pp. 143-147.
[16]	B. Dejaegher, M. S. Bloomfield, J. Smey-ers-Verbeke and Y. Vander Heyden, “Validation of a Fluorimetric Assay for 4-Aminophenol in Paracetamol Formulations,” Talanta, Vol. 75, No. 1, 2008, pp. 258-265. doi:10.1016/j.talanta.2007.11.029
[17]	R. N. Goyal, V. K. Gupta and S. Chatterjee, “Voltammetric Biosensors for the Determination of Paracetamol at Carbon Nanotube Modified Pyrolytic Graphite Electrode,” Sensors and Actuators B: Chemi-cal, Vol. 149, No. 1, 2010, pp. 252-258. doi:10.1016/j.snb.2010.05.019
[18]	S. S. Nair, S. A. John and T. Sagara, “Simultaneous Determination of Paracetamol and Ascorbic Acid Using Tetraoctylammonium Bromide Capped Gold Nanoparticles Immobilized on 1,6-Hexanedithiol Modified Au Electrode,” Electrochimica Acta, Vol. 54, No. 27, 2009, pp. 6837-6843. doi:10.1016/j.electacta.2009.06.077
[19]	C. E. Leite, G. O. Petersen, A. Lunardelli and F. V. Thiesen, “A High-Performance Liquid Chromatography Method for the Determination of Carbamazepine and Carbamaze-pine-10,11-Epoxide and Its Comparison with Chemiluminescent Immunoassay,” Clinical Chemistry and Laboratory Medicine, Vol. 47, No. 4, 2009, pp. 458-463. doi:10.1515/CCLM.2009.105
[20]	L. Hu, H. M. Martin, O. Arce-Bulted, M. N. Sugihara, K. A. Keating and T. J. Strath-mann, “Oxidation of Carbamazepine by Mn (VII) and Fe (VI): Reaction Kinetics and Mechanism,” Environmental Science & Technology, Vol. 43, No. 2, 2008, pp. 509-515. doi:10.1021/es8023513
[21]	C. Wang, Z. Wang, D. Han, Q. Wu and X. Zang, “Analysis of Carbamazepine in Tablet and Human Serum by Sweeping-Micellar Electrokinetic Chromatography Method,” Analytical Letters, Vol. 39, No. 9, 2006, pp. 1927-1939. doi:10.1080/00032710600721746
[22]	R. J. Per-chalski and B. J. Wilder, “Rapid Gas-Liquid Chromatographic Determination of Carbamazepine in Plasma,” Clinical Chemistry, Vol. 20, No. 4, 1974, pp. 492-493.
[23]	S. S. Kalanur and J. Seetharamappa, “Electrochemical Oxidation of Bioactive Carbamazepine and Its Interaction with DNA,” Analytical Letters, Vol. 43, No. 4, 2010, pp. 618-630. doi:10.1080/00032710903406870
[24]	M. S. Cámara, C. Mas-tandrea and H. C. Goicoechea, “Chemometrics-Assisted Simple UV-Spectroscopic Determination of Carbamazepine in Human Serum and Comparison with Reference Methods,” Journal of Biochemical and Biophysical Methods, Vol. 64, No. 3, 2005, pp. 153-166. doi:10.1016/j.jbbm.2005.07.001
[25]	C. Huang, Q. He and H. Chen, “Flow Injection Photochemical Spectrofluorimetry for the Determination of Carbamazepine in Phar-maceutical Preparations,” Journal of Pharmaceutical and Bio-medical Analysis, Vol. 30, No. 1, 2002, pp. 59-65. doi:10.1016/S0731-7085(02)00200-5
[26]	L. Yang, T. Guo, D. Y. Xia and L. S. Zhao, “Pharmacokinetics of Losartan and Its Active Carboxylic Acid Metabolite E-3174 in Five Ethnic Populations of China,” Journal of Clinical Pharmacy and Thera-peutics, Vol. 37, No. 2, 2012, pp. 226-231. doi:10.1111/j.1365-2710.2011.01279.x
[27]	R. N. Rao, S. S. Raju, R. M. Vali and G. G. Sankar, “Liquid Chromatogra-phy-Mass Spectrometric Determination of Losartan and Its Active Metabolite on Dried Blood Spots,” Journal of Chromatography B, Vol. 902, 2012, pp. 47-54. doi:10.1016/j.jchromb.2012.06.013
[28]	M. G. Quaglia, E. Donati, G. Carlucci, P. Mazzeo and S. Fanali, “Determination of Losartan and Hydrochlorothi- azide in Tablets by CE and CEC,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 29, No. 6, 2002, pp. 981-987. doi:10.1016/S0731-7085(02)00138-3
[29]	N. Erk, “Three New Spectrophotometric Methods Applied to the Simultaneous Determination of Hydrochlorothiazide and Irbesartan,” Die Pharmazie—An International Journal of Pharmaceutical Sciences, Vol. 58, No. 8, 2003, 2003, pp. 543-548.
[30]	A. R. Omayma, “Electrochemical Study of Hydrochlorothiazide and Its Determination in Urine and Tablets,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 34, No. 2, 2004, pp. 433-440. doi:10.1016/S0731-7085(03)00497-7
[31]	M. I. Pascual-Reguera, G. P. Parras and A. M. Diaz, “A Single Spectroscopic Flow-Through Sensing Device for Determination of Ciprofloxacin,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 35, No. 4, 2004, pp. 689-695. doi:10.1016/j.jpba.2004.03.002
[32]	M. S. Attia, Amr A. Essawy and A. O. Youssef, “Europium-Sensitized and Simultaneous pH-Assisted Spectrofluorimetric Assessment of Ci-profloxacin, Norfloxacin and Gatifloxacin in Pharmaceutical and Serum Samples,” Journal of Photochemistry and Photobiology A: Chemistry, Vol. 236, 2012, pp. 26-34. doi:10.1016/j.jphotochem.2012.03.007
[33]	S. Chen, F. Ding, Y. Liu and H. Zhao, “Electrochemiluminescence of Terbium (III)-Two Fluoroquinolones-Sodium Sulfite System in Aqueous Solution,” Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, Vol. 64, No. 1, 2006, pp. 130-135. doi:10.1016/j.saa.2005.07.006
[34]	S. M. Esponda, M. E. T. Padran, Z. S. Ferrera and J. J. S. Rodríguez, “Solid-Phase Microextraction with Micellar Desorption and HPLC-Fluorescence Detection for the Analysis of Fluoroquinolones Residues in Water Samples,” Analytical and Bioanalytical Chemistry, Vol. 394, No. 4, 2009, pp. 927-935. doi:10.1007/s00216-009-2629-8
[35]	M. Hernandez, F. Borrull and M. Calull, “Determination of Quinolones in Plasma Samples by Capillary Electrophoresis Using Solid-Phase Extraction,” Journal of Chromatography B: Biomedical Sciences and Applications, Vol. 742, No. 2, 2000, pp. 255-265. doi:10.1016/S0378-4347(00)00169-9
[36]	R. E. Ionescu, N. Jaffrezic-Renault, L. Bouffier, C. Gondran, S. Cosnier, D. G. Pinacho, M. P. Marco, F. J. Sánchez-Baeza, T. Healy and C. Martelet, “Impedimetric Immunosensor for the Specific Label Free Detection of Ciprofloxacin Antibiotic,” Biosensors and Bioelectronics, Vol. 23, No. 4, 2007, pp. 549-555.
[37]	B. S. Chang and D. H. Lowenstein, “Epilepsy,” New England Journal of Medicine, Vol. 349, No. 13, 2003, pp. 1257-1266. doi:10.1056/NEJMra022308
[38]	J. S. Duncan, J. W. Sander, S. M. Sisodiya and M. C. Walker, “Adult Epilepsy,” Lancet, Vol. 367, No. 9516, 2006, pp. 1087-1100. doi:10.1016/S0140-6736(06)68477-8
[39]	R. H. Mattson, J. A. Cramer, J. F. Collins, D. B. Smith, A. V. Delgado-Escueta, T. R. Browne, P. D. Williamson, D. M. Treiman, J. O. McNamara, C. B. McCutchen, R. W. Homan, W. E. Crill, M. F. Lubozynski, N. P. Rosenthal and A. Mayersdorf, “Comparison of Carbamazepine, Phenobarbital, Phenytoin, and Primidone in Partial and Secondarily Generalized Tonic-Clonic Seizures,” New England Journal of Medicine, Vol. 313, No. 3, 1985, pp. 145-151. doi:10.1056/NEJM198507183130303
[40]	Y. Zhang, S. U. Gei?en and C. Gal, “Carbamazepine and Diclofenac: Removal in Wastewater Treatment Plants and Occurrence in Water Bodies,” Chemosphere, Vol. 73, No. 8, 2008, pp. 1151-1161. doi:10.1016/j.chemosphere.2008.07.086
[41]	G. M. Escandar, D. González Gómez, A. E. Mansilla, A. M. de la Pe?a and H. C. Goicoechea, “Determination of Carbamazepine in Serum and Pharmaceutical Preparations Using Immobilization on a Nylon Support and Fluorescence Detection,” Analytica Chimica Acta, Vol. 506, No. 2, 2004, pp. 161-170. doi:10.1016/j.aca.2003.11.014
[42]	M. I. B. M. I. Beig, R. C. R. Chandra, A. T. A. Talwar, M. F. M. Fahim and A. K. A. Katyal, “Epileptic Seizure-Induced Hypertension and Its Prevention by Calcium Channel Blockers: A Real-Time Study in Conscious Telemetered Rats,” Canadian Journal of Physiology and Pharmacology, Vol. 87, No. 7, 2009, pp. 572-580. doi:10.1139/Y09-034
[43]	A. Shahzadi, I. Javed, B. Aslam, F. Muhammad, M. R. Asi and M. Y. Ashraf, “Therapeutic Effects of Ciprofloxacin on the Pharmacokinetics of Carbamazepine in Healthy Adult Male Volunteers,” Pakistan Journal of Pharmaceutical Sciences, Vol. 24, No. 1, 2011, pp. 63-68.